LEADER 01584nam  2200373 a 450 
001 9910701500903321
005 20120314075222.0
035   $a(CKB)5470000002418064
035   $a(OCoLC)780055124
035   $a(EXLCZ)995470000002418064
100   $a20120314d2009      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 04$aThe facts about naltrexone for treatment of opioid addiction$b[electronic resource]
210  1$a[Rockville, MD] :$cU.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment,$d2009.
215   $a1 online resource (16 unnumbered pages) $cillustrations
225 1 $aHHS publication ;$vno. (SMA) 09-4444
300   $aTitle from title screen (viewed on Mar. 14, 2012).
300   $a"Produced by JBS International, Inc., under Contract No. 270-04-7049 with the Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS)"--P. [16].
606   $aOpioid abuse$xTreatment$zUnited States
606   $aNaltrexone
615  0$aOpioid abuse$xTreatment
615  0$aNaltrexone.
712 02$aJBS International (Firm)
712 02$aCenter for Substance Abuse Treatment (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910701500903321
996   $aThe facts about naltrexone for treatment of opioid addiction$93495089
997   $aUNINA